be obtained, notwithstanding the development of acute graft-versus-host disease (GVHD), Uckan-Ç etinkaya et al.
1
hypothesized a possible role of the spleen in the balance between graft-versus-leukemia (GVL) and graft-versus-host (GVH) effect after DLI. Unfortunately, we do not have the opportunity to further analyze our data on the basis of this factor, as in our series none of the patients had previously undergone splenectomy.
We recently investigated the risk factors for GVHD after DLI administered with EDR in patients treated for CML in relapse following conventional allografting. 3 Two main factors emerged as predictors of the development of both grade II-IV acute and extensive chronic GVHD, the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and the last DLI, but only the first remained significant at multivariate analysis. 4 However, even in this series, none of the patients previously had splenectomy. The lack of splenectomized subjects in the DLI series clearly reflects the current therapeutic approach to CML that makes splenectomy obsolete.
Interestingly, a previous retrospective study analyzed the role of pretransplant splenectomy among 358 consecutive patients receiving HLA genotypically identical marrow grafts for CML. 4 At multivariate analysis, the incidence of late infections and the incidence or severity of acute or chronic GVHD were not influenced by previous splenectomy. On the other hand, splenectomy was associated with an increased risk of leukemia relapse. However, most of splenectomized patients were also at an advanced stage of disease, thus making extremely difficult to dissect the contribution of each factor. I was excited to read the paper by Inami et al. 1 in a recent issue of Leukemia regarding the evolution of a rare case of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph þ CML) into polycythemia vera with 1849G4T mutation of the Janus kinase 2 (JAK2 V617F ) mutation. Contrary to the group's suggestion, this was not the first case of coexisting BCR-ABL translocation and JAK2 V617F mutation reported in the literature. In 2005, Curtin et al.
2 described a patient with essential thrombocythemia who developed Ph þ CML 12 years later. Despite achieving a major cytogenetic response, treatment with imatinib did not control the thrombocytosis. Subsequently, JAK2 V617F mutation was found in the bone marrow sample of this patient. 3 More recently (after the publication of Inami), Hussein et al. 4 presented a case of myelofibrosis with JAK2 V617F mutation emerging after successful treatment of Ph þ CML. Several previous reports of transformation of PhÀ myeloproliferative disorders into Ph þ CML and vice versa may also potentially harbor JAK2 V617F mutation if ever tested. 5, 6 While it is unclear at the moment if these occurrences are true associations or just coincidental, the recent finding that JAK2 may be an important therapeutic target for Ph þ CML adds further excitement to the encouraging rate of progress in this field.
